$TSHA
Taysha Gene Therapies, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023021333 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $2.400M $4.700M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.988M $8.751M $11.47M
YoY Change -39.31% -23.7% 39.19%
% of Gross Profit
Research & Development $19.79M $12.51M $1.250M
YoY Change -14.39% 901.12% -77.27%
% of Gross Profit
Depreciation & Amortization $400.0K $300.0K $300.0K
YoY Change 33.33% 0.0% 837.5%
% of Gross Profit
Operating Expenses $25.78M $21.27M $1.250M
YoY Change -21.85% 1601.2% -96.1%
Operating Profit -$23.38M -$16.56M -$49.65M
YoY Change -29.11% -66.65% 54.72%
Interest Expense $1.440M $1.374M $849.0K
YoY Change 57.89% 61.84% 1186.36%
% of Operating Profit
Other Income/Expense, Net -$1.214M -$1.063M -$843.0K
YoY Change 36.71% 26.1% -1377.27%
Pretax Income -$24.60M -$17.62M -$50.11M
YoY Change -27.38% -64.83% 56.5%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$24.60M -$17.62M -$50.11M
YoY Change -27.38% -64.83% 56.48%
Net Earnings / Revenue -1024.92% -374.94%
Basic Earnings Per Share -$0.38 -$0.28 -$1.32
Diluted Earnings Per Share -$0.38 -$0.28 -$1.313M
COMMON SHARES
Basic Shares Outstanding 64.18M 63.47M 38.17M
Diluted Shares Outstanding 64.24M 63.26M 38.17M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.08M $63.43M $96.63M
YoY Change -31.94% -34.36% -57.75%
Cash & Equivalents $45.08M $63.43M $96.60M
Short-Term Investments
Other Short-Term Assets $510.0K $532.0K $941.0K
YoY Change -24.67% -43.46% 12.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $54.12M $72.36M $106.9M
YoY Change -29.57% -32.31% -55.39%
LONG-TERM ASSETS
Property, Plant & Equipment $14.14M $14.64M $55.12M
YoY Change -76.83% -73.44% 2104.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $304.0K $1.316M $3.965M
YoY Change -74.79% -66.81% 466.43%
Total Long-Term Assets $27.43M $29.24M $59.09M
YoY Change -58.12% -50.51% 1746.41%
TOTAL ASSETS
Total Short-Term Assets $54.12M $72.36M $106.9M
Total Long-Term Assets $27.43M $29.24M $59.09M
Total Assets $81.54M $101.6M $166.0M
YoY Change -42.71% -38.79% -31.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.77M $9.002M $22.00M
YoY Change -55.08% -59.08% 436.51%
Accrued Expenses $18.61M $16.60M $26.62M
YoY Change -1.98% -37.63% 78.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $337.0K $328.0K
YoY Change
Total Short-Term Liabilities $50.64M $54.46M $48.62M
YoY Change 17.9% 12.01% 155.88%
LONG-TERM LIABILITIES
Long-Term Debt $38.35M $38.16M $37.39M
YoY Change 2.06% 2.07%
Other Long-Term Liabilities $3.922M $4.004M $29.25M
YoY Change 12.7% -86.31% 2824.8%
Total Long-Term Liabilities $42.28M $42.17M $66.63M
YoY Change 2.96% -36.72% 6563.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $50.64M $54.46M $48.62M
Total Long-Term Liabilities $42.28M $42.17M $66.63M
Total Liabilities $118.7M $116.5M $115.3M
YoY Change 8.24% 1.13% 476.26%
SHAREHOLDERS EQUITY
Retained Earnings -$443.7M -$419.1M -$285.8M
YoY Change 38.83% 46.64%
Common Stock $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$37.11M -$14.95M $50.73M
YoY Change
Total Liabilities & Shareholders Equity $81.54M $101.6M $166.0M
YoY Change -42.71% -38.79% -31.64%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$24.60M -$17.62M -$50.11M
YoY Change -27.38% -64.83% 56.48%
Depreciation, Depletion And Amortization $400.0K $300.0K $300.0K
YoY Change 33.33% 0.0% 837.5%
Cash From Operating Activities -$18.77M -$20.19M -$40.80M
YoY Change -43.49% -50.53% 85.18%
INVESTING ACTIVITIES
Capital Expenditures -$48.00K $3.900M $8.427M
YoY Change -99.39% -53.72% 1478.09%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$3.000M
YoY Change -100.0% -100.0%
Cash From Investing Activities $48.00K -$3.900M -$11.43M
YoY Change -100.59% -65.87% 2039.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 377.0K -370.0K -242.0K
YoY Change -96.55% 52.89%
NET CHANGE
Cash From Operating Activities -18.77M -20.19M -40.80M
Cash From Investing Activities 48.00K -3.900M -11.43M
Cash From Financing Activities 377.0K -370.0K -242.0K
Net Change In Cash -18.34M -24.46M -52.47M
YoY Change -39.65% -53.4% 132.5%
FREE CASH FLOW
Cash From Operating Activities -$18.77M -$20.19M -$40.80M
Capital Expenditures -$48.00K $3.900M $8.427M
Free Cash Flow -$18.72M -$24.09M -$49.23M
YoY Change -26.14% -51.08% 118.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
6451000
CY2022Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8190000
CY2023Q1 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2022Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
CY2022Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201602Member
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2023Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#Liabilities
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001806310
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39536
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Taysha Gene Therapies, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3199512
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3000 Pegasus Park Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 1430
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75247
CY2023Q1 dei City Area Code
CityAreaCode
214
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
612-0000
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.00001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
TSHA
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64178567
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63425000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87880000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8933000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8537000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
72358000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96417000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2637000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101600000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14642000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14963000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10647000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10943000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1316000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1316000
CY2023Q1 us-gaap Assets
Assets
101600000
CY2022Q4 us-gaap Assets
Assets
126276000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
9002000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10946000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16602000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18287000
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28851000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33557000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
54455000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62790000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
38161000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
37967000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19928000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20440000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4004000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4130000
CY2023Q1 us-gaap Liabilities
Liabilities
116548000
CY2022Q4 us-gaap Liabilities
Liabilities
125327000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63473349
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63473349
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63207507
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63207507
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
404114000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
402389000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-419063000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401441000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-14948000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126276000
CY2023Q1 us-gaap Revenues
Revenues
4706000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12514000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38182000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8751000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11469000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
21265000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
49651000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16559000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-49651000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
319000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1374000
CY2022Q1 us-gaap Interest Expense
InterestExpense
672000
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1063000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-666000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17622000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-50317000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63260905
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63260905
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38174717
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38174717
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1675000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17622000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-14948000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95383000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5453000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-50317000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
50741000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-17622000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-50317000
CY2023Q1 us-gaap Depreciation
Depreciation
331000
CY2022Q1 us-gaap Depreciation
Depreciation
260000
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1250000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1675000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5329000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
300000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
309000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-128000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-194000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
400000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-271000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
359000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2544000
CY2023Q1 tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-250000
CY2022Q1 tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-779000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4706000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20185000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40939000
CY2022Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3000000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3900000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8427000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3900000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11427000
CY2023Q1 tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
387000
CY2022Q1 tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
151000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
50000
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
277000
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-33000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-233000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-370000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-107000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24455000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52473000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90517000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151740000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66062000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99267000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63425000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
96630000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
2637000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66062000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99267000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1125000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
419000
CY2023Q1 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
112000
CY2022Q1 tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
4513000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
18634000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000
CY2022Q1 tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
1250000
CY2023Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-419100000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the initial public offering (as an input into stock-based compensation), estimating manufacturing accruals and accrued or prepaid research and development expenses, the measurement of impairment of long-lived assets, and the allocation of consideration received in connection with the Astellas Transactions. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 tsha Derecognized Build To Suit Lease Asset Presented In Property Plant Equipment
DerecognizedBuildToSuitLeaseAssetPresentedInPropertyPlantEquipment
26300000
CY2023Q1 tsha Derecognized Build To Suit Lease Liability
DerecognizedBuildToSuitLeaseLiability
26500000
CY2023Q1 tsha Deferred Rent Liabiilities And Tenant Improvement Allowances
DeferredRentLiabiilitiesAndTenantImprovementAllowances
700000
CY2023Q1 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
200000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38182000
CY2022Q1 us-gaap Interest Expense
InterestExpense
672000
CY2022Q1 us-gaap Depreciation
Depreciation
260000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
309000
CY2022Q1 tsha Increase Decrease In Accrued Expense And Other Current Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherCurrentLiabilities
-779000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-233000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
18634000
CY2023Q1 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
4710000
CY2022Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
4840000
CY2023Q1 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
2568000
CY2022Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
2119000
CY2023Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
724000
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
724000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
373000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
388000
CY2023Q1 tsha Prepaid Bonus
PrepaidBonus
26000
CY2022Q4 tsha Prepaid Bonus
PrepaidBonus
18000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
532000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
448000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8933000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8537000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16615000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16605000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1973000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1642000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14642000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14963000
CY2022Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
36400000
CY2022Q4 tsha Construction In Progress And Finance Lease Right Of Use Asset
ConstructionInProgressAndFinanceLeaseRightOfUseAsset
26300000
CY2023Q1 us-gaap Depreciation
Depreciation
300000
CY2022Q1 us-gaap Depreciation
Depreciation
300000
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0774
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0772
CY2023Q1 tsha Accrued Severance
AccruedSeverance
3027000
CY2022Q4 tsha Accrued Severance
AccruedSeverance
1463000
CY2023Q1 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
2462000
CY2022Q4 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1473000
CY2023Q1 tsha Lease Liability Current
LeaseLiabilityCurrent
1752000
CY2022Q4 tsha Lease Liability Current
LeaseLiabilityCurrent
1521000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1242000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2519000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
866000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
390000
CY2023Q1 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
112000
CY2022Q4 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
2081000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
690000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
650000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16602000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18287000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
708000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
535000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
243000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
194000
CY2023Q1 us-gaap Lease Cost
LeaseCost
951000
CY2022Q1 us-gaap Lease Cost
LeaseCost
729000
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M17D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M17D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y3M7D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y5M12D
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1051
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1051
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
692000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
363000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2255000
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
341000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2918000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
454000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3021000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
454000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2485000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
399000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2577000
CY2023Q1 tsha Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
19721000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
32977000
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1648000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11625000
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
311000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
21352000
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1337000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1424000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
328000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19928000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1009000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
21352000
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1337000
CY2022Q4 tsha Probability Of An Option Exercise
ProbabilityOfAnOptionExercise
0.50
CY2023Q1 us-gaap Revenues
Revenues
4700000
CY2023Q1 us-gaap Deferred Revenue
DeferredRevenue
28900000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P0Y9M18D
CY2021Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0700
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-08-01
CY2021Q3 tsha Percentage Of Prepayment Of Facility
PercentageOfPrepaymentOfFacility
0.075
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3000000.0
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2021Q3 tsha Percentage Of Annual Default Interest Rate
PercentageOfAnnualDefaultInterestRate
0.05
CY2023Q1 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1300000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6667000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
13333000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1839000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
38161000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1067682
CY2023Q1 tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod
3160375
CY2023Q1 tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
-1597604
CY2023Q1 tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod
-2603971
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5234424
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
1800
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1675000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5329000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17622000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50317000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63260905
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63260905
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38174717
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38174717
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6179633
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7602457
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-021333-index-headers.html Edgar Link pending
0000950170-23-021333-index.html Edgar Link pending
0000950170-23-021333.txt Edgar Link pending
0000950170-23-021333-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img38645653_0.jpg Edgar Link pending
img38645653_1.jpg Edgar Link pending
img38645653_10.jpg Edgar Link pending
img38645653_11.jpg Edgar Link pending
img38645653_12.jpg Edgar Link pending
img38645653_13.jpg Edgar Link pending
img38645653_14.jpg Edgar Link pending
img38645653_15.jpg Edgar Link pending
img38645653_16.jpg Edgar Link pending
img38645653_17.jpg Edgar Link pending
img38645653_18.jpg Edgar Link pending
img38645653_19.jpg Edgar Link pending
img38645653_2.jpg Edgar Link pending
img38645653_3.jpg Edgar Link pending
img38645653_4.jpg Edgar Link pending
img38645653_5.jpg Edgar Link pending
img38645653_6.jpg Edgar Link pending
img38645653_7.jpg Edgar Link pending
img38645653_8.jpg Edgar Link pending
img38645653_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-20230331.htm Edgar Link pending
tsha-20230331.xsd Edgar Link pending
tsha-ex31_1.htm Edgar Link pending
tsha-ex31_2.htm Edgar Link pending
tsha-ex32_1.htm Edgar Link pending
tsha-ex32_2.htm Edgar Link pending
tsha-20230331_cal.xml Edgar Link unprocessable
tsha-20230331_lab.xml Edgar Link unprocessable
tsha-20230331_def.xml Edgar Link unprocessable
tsha-20230331_pre.xml Edgar Link unprocessable
tsha-20230331_htm.xml Edgar Link completed